Orbicular Secures Canada Approval for First Generic Ozempic

Health Canada has approved Orbicular's generic version of Ozempic® (semaglutide injection), developed with OneSource Specialty Pharma. This approval makes Orbicular the first company to enter the Canadian semaglutide market with a generic product.

Approval Details

OneSource Specialty Pharma announced that its partner, Orbicular, has received approval from Health Canada for its generic semaglutide injection, which is bioequivalent to Ozempic®. This achievement makes Orbicular the first to launch a generic semaglutide product in Canada.

OneSource provided full manufacturing support for this filing from its US FDA-approved facility in Bengaluru, India. This confirms OneSource's ability to manufacture complex pharmaceutical products for highly regulated markets.

Significance for OneSource Pharma

The approval is a major step for OneSource Specialty Pharma, highlighting its role as a capable Contract Development and Manufacturing Organisation (CDMO) for complex drug-device combinations and specialty injectables. It opens a significant global market for semaglutide, a drug class in high demand for diabetes and weight management.

This success follows a recent tentative US FDA approval for the same product, further strengthening OneSource's position in the competitive peptide-based injectable segment.

Manufacturing and Development Background

OneSource Specialty Pharma, a pure-play CDMO, has been actively positioning itself in complex pharmaceutical segments. In April 2026, its partner Orbicular secured a tentative US FDA approval for a generic Ozempic®, with OneSource providing manufacturing support from its Bengaluru facility.

The company's flagship facility in Bengaluru has maintained US FDA compliance, holding a Voluntary Action Indicated (VAI) classification following a March 2025 inspection. This is critical for serving regulated markets.

OneSource has also undergone significant corporate restructuring, integrating various business units and listing on Indian stock exchanges. The company is expanding capacity for drug-device combinations, with Phase 1 slated for completion by December 2025.

Investor Implications

• Investors gain insight into OneSource's expanding CDMO footprint in high-value therapeutic areas.
• The company boosts its reputation for supporting complex, regulated product launches globally.
• This creates opportunities for commercialization and revenue generation from the Canadian market.
• This milestone strengthens OneSource's position in the growing peptide-based drug manufacturing sector.

Potential Challenges Ahead

While the approval is positive, the generic pharmaceutical market is highly competitive. Intense competition and potential price erosion could impact profit margins for the drug and OneSource's CDMO services. Continued adherence to stringent US FDA and global regulatory standards is paramount, as non-compliance could lead to regulatory bans or affect future approvals.

Competitive Landscape

OneSource operates in a growing Indian CDMO sector focused on complex peptides and injectables, driven by the significant demand for GLP-1 agonists. Peers like Sai Life Sciences and Granules India (which acquired Senn Chemicals) are also expanding peptide capabilities. The global peptide CDMO market is expected to grow significantly, with Indian players aiming to capture a larger share.

Market Context

• The global market for GLP-1 based therapies is projected to exceed $150 billion by 2030.
• India's peptide CDMO market is expected to grow at a compound annual growth rate of 14% over the next five years.

What to Watch Next

• Monitor the commercialization progress and sales uptake of generic Ozempic® in Canada.
• Watch for OneSource's role in potential launches in other international markets.
• Track the completion of ongoing capacity expansions and their utilization.
• Observe OneSource's new CDMO partnerships in complex injectables and drug-device combinations.
• Assess the impact of generic competition on pricing and OneSource's revenue streams from this product.